ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

ICON Public Limited Company

J.P. Morgan analyst Casey Woodring maintained a Hold rating on Icon yesterday and set a price target of $165.00. Woodring covers the Healthcare sec...

J.P. Morgan Reaffirms Their Hold Rating on Icon (ICLR)

Icon ( ($ICLR) ) just unveiled an announcement. ICON plc is a world-leading clinical research organization that provides integrated consulting, cli...

ICON Shareholders Approve All Resolutions at July 31 AGM, Bolstering Capital Flexibility

RBC Capital analyst Ryan Halsted maintained a Buy rating on Icon yesterday and set a price target of $185.00. The company’s shares closed yesterday...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ICLR	$164.51	+2.07%	388.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ICLR	$164.51	+2.1%	388.37K
3
4
5
6

ICLR

ICLR

Get ICON Public Limited Company Data in Excel

Get ICON Public Limited Company Data in Excel